复星和1,25-二氧维生素D降低了Lingo-1水平,并改善了哈马林诱导的基本震的行为,这表明潜在的治疗益处
Zeynab Pirmoradi1, Mohsen Nakhaie2, Hoda Ranjbar1
1Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, 76198-13159, Iran.
Scientific reports
|April 29, 2024
概括
复星和维生素D3的联合治疗可以通过改善运动和认知功能来帮助管理基本震 (ET) 症状. 这种组合调节Sirt1和Lingo-1水平,提供潜在的神经保护,防止ET相关的退化.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 基本震 (ET) 是一种影响运动和认知功能的神经疾病.
- 增加小脑Lingo-1表达与更高的ET风险和神经退行有关.
- 在ET中,Sirt1蛋白提供神经保护,其活性由白醇 (Res) 和1,25-二氧维生素D3 (VitD3) 增强.
研究的目的:
- 在关键震的老鼠模型中研究复星和维生素D3联合治疗的神经保护作用.
- 为了确定联合治疗是否调节Sirt1和Lingo-1基因表达水平.
- 评估联合Res-VitD3对ET相关的运动和认知缺陷的影响.
主要方法:
- 哈马林注射模型被用于诱导成年大鼠的ET类症状.
- 在暴露于harmaline之前,老鼠每天接受内注射resveratrol (5 mg/kg) 和维生素D3 (0.1 mg/kg).
- 使用定量PCR (qPCR) 来测量Sirt1和Lingo-1基因表达水平.
主要成果:
- 哈马林暴露会损害运动协调,增加,并导致认知功能障碍.
- 联合Res-VitD3治疗显著降低了震的严重程度,抚养和记忆障碍.
- 同时治疗调节了Sirt1和Lingo-1基因表达,具有有益的行为效应,单独治疗时没有观察到.
结论:
- 在ET模型中,复星和维生素D3的联合治疗有效地改善了运动器官和认知缺陷.
- 似乎Res-VitD3的协同效应是通过Sirt1和Lingo-1通路的调节来实现的.
- 建议同时服用白醇和维生素D3来控制基本的症状,因为它们具有相辅相成的神经保护作用.
相关概念视频
Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183


